Background 1 5
, for detailed reference datasets on the online website). According to the identification stage, 6 8 it can be divided into clinical and preclinical models; According to the research object, it can be 6 9
divided into in vivo model and in vitro model; Genome, transcriptome, proteome model and logical 7 0 model (logical combination of events) were obtained according to the classification of the technical 7 1 system. According to the model related event types mainly include SNV (simple nucleotide 7 2 variation), CNV (copy number variation), EXP (expression), SV (structural variation), SPV (splice 7 3 variant) and LN (cell lineage) [see Table S1 for more event types]. We standardized the data from 7 4 these sources, including tissue type, cancer type, drug, gene and model presentation (see Table S2 for 7 5 detailed process description). Eventually, we obtained about 154,100 models of 144 cancers of 30 7 6 tissue types, involving 1,040 different types of anticancer drugs (hormones, small molecules, 7 7 vaccines, antibody drugs, etc.). In order to build an efficient research resource of pharmacogenetics, 7 8
we integrated various information about drugs including chemical composition, structure, target, 7 9 signal pathway and classification, and information about genes includes functional description and 8 0 associated functional signaling pathways (see Table S3 for a list of detailed information sources). 8 1 8 2
WEBSERVER CONSTRUCTION 8 3
Based on the above integration process, we constructed an anticancer pharmacogenetics model 8 4 resource, iGMDR, whose code is open source and available on GitHub repository 8 5 (https://github.com/ModelLAB-ZJU/iGMDR) based on the GPLv3 license. The iGMDR online site 8 6 was built on an Apache HTTP server, all model data was stored in a MySQL database, and PHP was 8 7 used for backstage and front-end interactions (see Figure 1 ). Users can fully browse and download the 8 8 genetic models of anticancer drugs through different data types (cancer, tissue, drug, and gene). Based 8 9
on the intuitive understanding that pharmacogenetics researchers are usually interested in genetic 9 0 models involving specific genes and anticancer drugs, we also designed the relevant search and 9 1 profile interfaces, and the feedback information will be displayed visually. Specific drugs exhibitions 9 2 will include general information (composition, targets, signaling pathways, classification, and external 9 3 database ID), conformer structure (small molecule drugs), models of drug-related genes, the cancer 9 4 tissue distribution of drug-related models, the signaling pathways and function enrichment of drug-9 5 related models, the drug-gene interaction network (the network was built through the number of drug-9 6 related models), and the drug-related model list. Specific gene profiling page describes the basic 9 7 information of the gene (gene summary, categories, and external database ID), gene-related signaling 9 8 pathways and functions, gene-associated anticancer drugs, the normal tissue distribution of gene 9 9 expression in human, the distribution of gene-related drug targets and signaling pathway, and gene-1 0 0 drug interaction network (constructed by the number of gene-related models). These profiling and 1 0 1 data presentations will facilitate the understanding of specific anticancer drug and gene-related 1 0 2 genetic models. gene. STK11 is a tumor suppressor that functions in the regulation of cell polarity, TP53 activity, and 1 0 8 cell-cycle arrest. In our integrated resources, we can find that the most influential cancer tissue related 1 0 9
to STK11 is Lung. For Lung cancers harboring STK11 mutations, we can predict the intervention 1 1 0 effect of the corresponding 113 drugs. Of course, the genome variation of cancer patients is complex 1 1 1 and diverse, and the genetic indicator from a single model may not be able to predict the final efficacy 1 1 2 of drugs, so our resources also provide other indicators of genetic variation to predict the intervention 1 1 3 effect of these 113 drugs. NSCLC have been recommended to test the status of STK11 [17, 18] . As shown in Figure 2 , we 1 1 9 constructed a gene-related model network of STK11 in our resources, including all the genetic 1 2 0 indicators of these 113 drugs (red dots). Importantly, these drug interventions for NSCLC can be 1 2 1 found in this network. With the help of this global model network, treatment strategies can be tailored 1 2 2 to a patient's own genetic defects. 1 2 3
The essence of tumorigenesis has been widely believed to be the result of aberrant cell signal 1 2 4 transduction caused by genetic variation that further disrupt these signaling pathways as cancer 1 2 5 progresses, and this process will become much more complicated than that of tumorigenesis [19] . 1 2 6
Therefore, the traditional targeted therapy for a single target is often less effective for cancer 1 2 7 treatment. Through the query of our resources, multiple targeted drugs are sensitive in terms of Lung 1 2 8 cancer with STK11 gene defects, and the genes targeted by these therapeutic drugs participate in 1 2 9 different signaling pathways (see Table S4 ). In addition, the predictive genes involved in these drug-1 3 0 related treatment models are also involved in these different signaling pathways (Figure 2 ). Based on 1 3 1 this, we can design new treatment schemes to deal with the same or different pathways with abnormal 1 3 2 signal transduction to improve the therapeutic effect of cancer. In other words, we can use this 1 3 3 network to further infer new pharmaceutical strategies. 1 3 4
Interestingly, some kind of strategy at the signaling pathway level and important inferences for 1 3 5 cancer treatment had been really reflected in the model networks that we built on this resource. 1 3 6 STK11 is frequently mutated in NSCLC that acts as a tumor suppressor by activating AMPK (5′ 1 3 7 AMP-activated protein kinase) signaling，whereas loss of STK11 by point mutation or deletion 1 3 8 suppresses AMPK, leading to increased mTOR signaling. Recently researchers have investigated the 1 3 9 effects of STK11 mutation and mTOR inhibition on cell signaling pathways in NSCLC cell lines, 1 4 0 suggesting a feedback mechanism that STK11 mutant cell lines increased insulin-like growth factor 1 4 1 receptor (IGFR) activity, and inhibition of the IGFR activity was shown to downregulate the mTOR 1 4 2 pathway [20] . The results supported the investigation of IGFR inhibitors in combination with drugs 1 4 3 targeting the mTOR pathway, particularly for tumors bearing STK11 alterations [21] . 1 4 4
By dephosphorylation of PIP3, PTEN negatively regulates PI3K/AKT leading to tumor 1 4 5 suppression in NSCLC [22] . PTEN inactivation/loss therefore increases activity of the PI3K-AKT-1 4 6 mTOR pathway and further suggest that NSCLC patients might afford an opportunity for exploitation 1 4 7 of anti-PI3K-AKT/mTOR-targeted therapies. Several studies have shown this subset of lung cancers 1 4 8 treated with PI3K/AKT inhibitors combining with mTOR inhibitors (rapamycin) [16] . Until now, 1 4 9 targeting of TP53 signaling has proved to be highly disappointing. However, recent studies indicate 1 5 0 abundant crosstalk between TP53 and the AKT/mTORC1 signaling pathway can determine the choice 1 5 1 of response to TP53. These results could have important pharmacological consequences for the 1 5 2 potential development of PI3K/Akt inhibitors against TP53-deficient cancers [23, 24] . 1 5 3
To sum up, the integrated model information will provide guidance for personalized treatment of 1 5 4 cancer patients, and users can also infer new therapeutic strategies by connecting the model with the 1 5 5 signal transduction network so as to improve the defects of single-targeted treatment (see Figure 3 ). 1 5 6
These directions may help to identify patients who would most benefit from alternative single or dual 1 5 7 pathway inhibition potentially leading to a revision in current molecular testing guidelines, and also 1 5 8 demonstrate the advantages of integrating resources. Drug genetics model can effectively achieve precision anticancer treatment [25, 26] . To release the 1 6 2 value of existing data, we have established a draft principle to collect the drug genetics model. 1 6 3 iGMDR is the first integrated data resource to provide a predictive model for the therapeutic effect of 1 6 4 anticancer drugs. Compared with the resources we have integrated, the current resources only provide 1 6 5 a single genetics model of anticancer drug ("experimental statistics" for CCLE and GDSC or "clinical 1 6 6 guidelines" for NCCN guidelines and FDA drug labels), and the data volume is also different by 1 6 7 orders of magnitude, which greatly limits the application value of such data. The interactive design 1 6 8 and data visualization of the iGMDR website provides both macro and micro insights for 1 6 9 pharmacogenetics researchers in the cancer drug genetics model. For example, we can design a new 1 7 0 sequencing panel for cancer drug efficacy prediction; We can link drug-related targets and signaling 1 7 1 pathways to design combinatorial strategies for cancer therapy. In conclusion, iGMDR will continue 1 7 2 to integrate relevant pharmacogenetic studies into cancer clinical and research therapy. 
